PPARG and lung carcinoma: Besides experimental data supporting the use of PPARγ agonists as a monotherapy for lung cancer, as discussed above, multiple PPARγ agonists demonstrate synergy with commonly used traditional chemotherapeutic drugs such as cisplatin, carboplatin, and paclitaxel, inhibiting proliferation of multiple NSCLC cell lines and suppressing tumor growth in a xenograft lung cancer model [69, 70].